508. Bone Marrow Failure: Acquired: Poster II

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor–Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Absolute Immature Platelet Count As an Accessible Diagnostic Tool for Aplastic Anemia Vs. Immune Thrombocytopenia

Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia

Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria: Data from Danicopan and Pegcetacoplan Trials

Complement Mediated Immune Activation in HLA Class I Alloimmunized Immune Aplastic Anemia Imputed from Single Cell Analysis of Peripheral Cell Subsets

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial

Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin+Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study

Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study

Higher Graft Failure after Haploidentical in Comparison to Matched Related and Unrelated Stem Cell Transplantation for Severe Aplastic Anemia: A Single-Center Retrospective Study

KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Single Cell Profiling of Hematopoietic Stem and Progenitor Cells in Pediatric Acquired Aplastic Anemia

Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia